Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.37 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359120 | 0.86 | MAPT (0.42) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL19409420 | 0.84 | MAPT (0.36) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL11400035 | 0.84 | AKT1 (0.35) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL11400038 | 0.81 | AKT1 (0.35) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL6259565 | 0.79 | RECQL (0.41) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL6259567 | 0.79 | RECQL (0.41) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL3423749 | 0.77 | MAPT (0.41) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL4896000 | 0.76 | MAPT (0.44) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL6470886 | 0.76 | MAPT (0.40) | AKT1MAPTBCHENPC1RAB9A | |
| SCHEMBL3697930 | 0.76 | ALDH1A1 (0.42) | AKT1MAPTBCHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-09 | — | — | US | disclosed |
| US-9445606-B2 | Use of 4-hydroxydihydrochalcones and their salts for enhancing an impression of sweetness | SYMRISE AG (DE) | 2016-09-20 | — | — | US | disclosed |
| EP-2849768-A1 | EXTRACT OF GREYIA RADLKOFERI AND USE THEREOF | University of Pretoria (ZA) | 2015-03-25 | — | — | EP | disclosed |
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | MARTINEAU LOUIS C (CA) | 2014-05-15 | — | — | US | disclosed |
| WO-2013171720-A1 | EXTRACT OF GREYIA RADLKOFERI AND USE THEREOF | UNIVERSITY OF PRETORIA (ZA) | 2013-11-21 | — | — | WO | disclosed |
| US-20100233102-A1 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS | SYMRISE GMBH & CO. KG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-1996212-A2 | COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS | Rutgers, The State University of New Jersey (US) | 2008-12-03 | — | — | EP | disclosed |
| CN-101058594-A | Sarcandra glabra effective constituent, preparation method thereof, medicament composition and use of the same | INST MATERIA MEDICA CAMS (CN) | 2007-10-24 | — | — | CN | disclosed |
| WO-2007109217-A2 | COMPOUNDS FROM AN EXTRACT OF ARTEMISIA AND METHODS FOR TREATING DISORDERS | RUTGERS, THE STATES UNIVERSITY OF NEW JERSEY (US) | 2007-09-27 | — | — | WO | disclosed |
| US-3974299-A | DIETETIC SWEETENER | DYNAPOL (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | UQCRC2, UQCRC1, TIMM50 | AKT1 4588/4885MAPT 4702/4885BCHE 1454/4885 |
| US-20230045522-A1 | COMPOSITIONS AND METHODS TO MODULATE GLUCOSE HOMEOSTASIS | GCKR, G6PC1, GPR119 | AKT1 1405/4885MAPT 1932/4885BCHE 3949/4885 |
| US-20100233102-A1 | USE OF 4-HYDROXYDIHYDROCHALCONES AND THEIR SALTS FOR ENHANCING AN IMPRESSION OF SWEETNESS | TAS2R4, TAS2R1, TAS2R20 | AKT1 3738/4885MAPT 4633/4885BCHE 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.